Revvity Inc vs Visa Inc — how do they compare? Revvity Inc trades at $110.1 (market cap $11.87B), while Visa Inc trades at $355.62 (market cap $685.71B). The key difference: Visa Inc is far larger — about 57.8× Revvity Inc's market cap, and Visa Inc pays the higher dividend (0.74%). Which is the better fit depends on your goals.
| RVTY | V | |
|---|---|---|
Market Cap | $11.87B | $685.71B |
Sector | Technology | Financials |
52-Week High | $117.75 | $365.14 |
52-Week Low | $82.26 | $295.52 |
Enterprise Value | $14.36B | $696.30B |
Dividend Yield | 0.26% | 0.74% |
Volume | — | 10,431,336 |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue growth remains robust, reaching $40B in 2025, and profitability is high with a net income margin of 51.68%. Recent news highlights Visa's focus on AI-driven commerce and stablecoin partnerships, positioning it for future payment innovations.
The stock offers a compelling long-term investment case with 85% analyst buy ratings and a $396.70 consensus price target, implying 11% upside. Key risks include competitive threats from fintech and regulatory pressures. Visa's strong cash flow and dividend payments provide shareholder value, but investors should monitor execution on AI initiatives and macroeconomic impacts on consumer spending.
Trailing returns across standard periods
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →